financetom
Business
financetom
/
Business
/
National Bank on Couche-Tard Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Bank on Couche-Tard Q4
Jun 27, 2025 10:48 AM

01:33 PM EDT, 06/27/2025 (MT Newswires) -- National Bank views Couche-Tard's fourth-quarter performance to be largely in line, with better-than-expected fuel and merchandising sssg offset by heightened costs.

A lower-than-expected effective tax rate aided EPS by $0.03 compared with National Bank estimates, writes analyst Vishal Shreedhar.

Couche-Tard estimates have been trimmed slightly -- F2026 goes to $2.94 from $3.02 and F2027 goes to $3.37 from $3.45.

Couche-Tard also indicated the timeline with Seven & i is expected to be shorter vs. longer. "We believe that a resolution with Seven & i will be a positive catalyst for the shares. "

Maintain Outperform rating; price target of $81.

Price: 68.15, Change: -0.75, Percent Change: -1.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies
Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies
Jun 28, 2024
12:29 PM EDT, 06/28/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Friday it secured $3.4 million in nondilutive funding to support its phase 2 trial of intranasal foralumab in nonactive secondary progressive multiple sclerosis and advance research in Alzheimer's disease. We continue to explore all avenues to pursue further nondilutive funding in the near term, acting Chief...
BranchOut Food Closes $1.4 Million Public Offering
BranchOut Food Closes $1.4 Million Public Offering
Jun 28, 2024
12:18 PM EDT, 06/28/2024 (MT Newswires) -- BranchOut Food ( BOF ) said Friday it has closed its underwritten public offering of 1.75 million common shares at $0.80 apiece for gross proceeds of about $1.4 million. The underwriters have a 45-day option to buy up to 262,500 additional shares at the public offering price, minus underwriting discounts, the company said....
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial
Jun 28, 2024
12:28 PM EDT, 06/28/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday results from a phase 3 study of nipocalimab in generalized myasthenia gravis were positive. Patients treated with nipocalimab plus standard of care achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the Myasthenia Gravis- Activities of Daily Living score...
Dollar Tree Undervalued Amid Market Skepticism, Holds Potential Upside in Family Dollar Closures, UBS Says
Dollar Tree Undervalued Amid Market Skepticism, Holds Potential Upside in Family Dollar Closures, UBS Says
Jun 28, 2024
12:35 PM EDT, 06/28/2024 (MT Newswires) -- Dollar Tree ( DLTR ) is facing an excessively negative market perception that is creating a 6-to-1 upside downside skew, which is quite compelling, UBS Securities said in a note Friday. The bank said Dollar Tree's ( DLTR ) shares have weakened due to concerns about its long-term sales and margin potential, rising...
Copyright 2023-2026 - www.financetom.com All Rights Reserved